Caribou Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 9.26K shares, a 38.29% decline year-over-year.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 6.20K shares.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 15.00K shares, a 91.77% decline from fiscal 2024.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 182.22K shares, a 20.17% decline from fiscal 2023.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 228.26K shares, a 67.25% decline from fiscal 2022.
- Caribou Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 696.91K shares, a 71.76% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 9.26K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 15.46K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 6.20K shares 10-Q · filed 2026-05-07 | 21.20K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 15.00K shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 15.00K shares derived: sum of 4 quarters · filed 2026-03-05 |
| 2025-06-30 | 15.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 15.00K shares derived: sum of 4 quarters · filed 2026-03-05 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-08 | 47.87K shares derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 182.22K shares 10-K · filed 2026-03-05 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 200.56K shares derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-06-30 | 47.87K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 283.96K shares derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-03-31 | 134.35K shares 10-Q · filed 2024-05-07 | 322.18K shares derived: sum of 4 quarters · filed 2025-03-10 |
| 2023-12-31 | 18.34K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | 228.26K shares 10-K · filed 2025-03-10 |
| 2023-09-30 | 83.41K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 252.17K shares derived: sum of 4 quarters · filed 2024-03-11 |
| 2023-06-30 | 86.08K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 284.81K shares derived: sum of 4 quarters · filed 2024-03-11 |
| 2023-03-31 | 40.43K shares 10-Q · filed 2023-05-09 | 347.49K shares derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-12-31 | 42.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | 696.91K shares 10-K · filed 2024-03-11 |
| 2022-09-30 | 116.05K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 896.50K shares derived: sum of 4 quarters · filed 2023-03-09 |
| 2022-06-30 | 148.76K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | |
| 2022-03-31 | 389.86K shares 10-Q · filed 2022-05-09 | |
| 2021-12-31 | 241.84K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | 2.47M shares 10-K · filed 2023-03-09 |
| 2021-06-30 | 1.04M shares 10-Q · filed 2021-09-02 | |
| 2021-03-31 | 584.61K shares 10-Q · filed 2021-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |